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Background Concomitant targeting of LDL-C, non-HDL-C and apoB levels is suggested for subjects at high cardiovascular risk‡§.
Methods This analysis of a randomized, double blind study assessed the effect of ezetimibe/simvastatin (E/S) + extended release niacin (N) vs 
E/S and/or N on the attainment of specified LDL-C, non-HDL-C and apoB levels in type IIA/IIB hyperlipidemic (HL) subjects, and in subgroups with 
high CHD risk (+/-AVD), diabetes (DM), metabolic syndrome (MetS/nonDM) and nonDM/nonMetS. Patients received E/S 10/20mg + N to 2g or E/S 
10/20mg for 64 wks, or N to 2g for 24 wks then E/S 10/20mg + N 2g or E/S 10/20mg for 40 wks more.
Results A significantly greater number of HL patients on E/S+N attained concomitant levels of LDL-C, non-HDL-C and apoB (cluster 1: <100, <130 and 
<90mg/dl for high CHD risk; cluster 2: <70, <100 and <80 mg/dl for very high CHD risk; table) compared with N and E/S at 24 wks and E/S at 64 wks. 
Attainment rates at 24 and 64 wks in all subgroups were significantly greater with E/S+N vs N, and generally numerically to statistically greater with E/
S+N vs E/S. Greater attainment of all three specified lipid levels was most consistent with single level attainment of non-HDL-C (table).
Conclusion Our results indicate that combination E/S+N is an effective therapeutic option for improving attainment of lipid goals in HL patients. 
Attainment of non-HDL-C levels best supported concomitant attainment of all three lipid endpoints. The outcome benefits of E/S+N await results of 
ongoing clinical trials.
% of patients attaining treatment levels
24 weeks 64 weeks
E/S+N† E/S† N† E/S+N† E/S†
Cluster 1: LDL-C <100mg/dl and nonHDL-C <130mg/dl and ApoB <90mg/dl‡
Full cohort 77.3 54.6* 6.7* 77.3 57.1*
High risk w/o AVD 76.8 47.1* 2.0* 78.3 69.0
High risk w/ AVD 64.4 71.9 5.6* 66.7 59.3
DM 74.1 60.0 2.1* 79.6 75.0
MetS/nonDM 72.6 47.3* 7.1* 73.0 50.0*
NonDM/nonMetS 82.5 61.4* 8.4* 80.4 59.2*
Cluster 2: LDL-C <70mg/dl and nonHDL-C <100mg/dl and ApoB <80mg/dl§
Full cohort 62.1 31.2* 1.8* 58.3 28.6*
High risk w/o AVD 62.5 38.2* 2.0* 60.9 41.4
High risk w/ AVD 46.7 40.6 2.7* 54.5 37.0
DM 63.8 40.0* 2.1* 61.2 41.7
MetS/nonDM 53.4 27.5* 3.6* 54.9 30.5*
NonDM/nonMetS 68.9 32.5* 1.2* 60.1 22.4*
† Number of patients assessed for E/S+S, E/S and N at 24 wks and E/S+N and E/S at 64 wks respectively in: Full cohort (383, 205,163, 321, 182); High risk w/o AVD (56, 34, 25, 46, 
29); High risk w/ AVD (45, 32, 18, 33, 27); DM (58, 30, 23, 49, 24); MetS/nonDM (146, 91, 56, 122, 82); NonDM/nonMetS (177, 83, 83, 148, 76); ‡suggested for high-risk patients 
and §highest-risk patients with cardiometabolic risk (Brunzell JD et al, JACC 2008, 51:1512-24); * 95% CI for OR ratio for treatment comparison (E/S+N vs E/S or E/S+N vs N) 
excludes 1. Some variability in the results may be due to the small sample sizes in the subgroups. % attaining single treatment levels for LDL-C <70mg/dl, non-HDL-C <100 mg/dl and 
ApoB <80mg/dl in the full cohort at 24 wks were E/S+N (72.9, 78.8, 64.0%): E/S (49.5, 55.7, 32.2%); N (1.8, 5.4, 2.5%) and at 64 wks were E/S+N (65.3, 75.3, 64.8%); E/S (38.2, 
51.7, 35.7%). % attainment for LDL-C <100mg/dl, non-HDL-C <130 mg/dl and ApoB <90mg/dl in the full cohort at 24 wks were E/S+N (90.5, 90.0, 77.3%); E/S (92.5, 90.1, 54.6%); 
N (18.7, 28.9, 7.4%) and at 64 wks were E/S+N (86.2, 86.2, 77.6%); E/S (86.0, 85.0, 57.7%)
